US · Healthcare · Biotechnology
EPS came in at -0.20 against a street estimate of -0.70 — a beat of 71.4%.
Analysts rate Assembly Biosciences Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $52.00.
| Fund | Stake |
|---|---|
| Paradigm Biocapital Advisors LP | 7.83% |
| Farallon Capital Management, L.L.C. | 6.18% |
| RA Capital Management, LLC | 5.14% |
| COMMODORE CAPITAL LP | 5.04% |
| HHG PLC | 4.28% |
| Parkman Healthcare Partners LLC | 3.63% |
| Vanguard Capital Management, LLC | 2.47% |
| StemPoint Capital LP | 1.87% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ASSEMBLY BIOSCIENCES, INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Marketable Securities: $320.4 million as of June 30, 2026 ($248.1 millio | 2026-08-13 |
| Acquisition completed · Q3 2026 ASSEMBLY BIOSCIENCES, INC. – 8-K SUMMARY DOCUMENT STATUS • This is a Form 8-K filing dated August 13, 2026, disclosing Q2 2026 financial results (qua | 2026-08-13 |
| Board / officer change · Q2 2026 ASSEMBLY BIOSCIENCES, INC. (ASMB) - 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 4, 2026 • Stock Incentive Plan share pool in | 2026-06-05 |
| Material agreement · Q2 2026 ASSEMBLY BIOSCIENCES, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company completed an underwritten public offering on May 26, 2026, raising net proceeds | 2026-05-26 |
| Reg FD disclosure · Q2 2026 ASSEMBLY BIOSCIENCES, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Assembly Biosciences, Inc. (ticker: ASMB, Nasdaq) • Filing date: May 22, 2026 • | 2026-05-22 |
| Quarterly report · Q1 2026 ASSEMBLY BIOSCIENCES, INC. - FORM 10-Q SUMMARY Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Cash and marketable securities: $226.6 million a | 2026-05-07 |
| Proxy statement · Q2 2026 ASSEMBLY BIOSCIENCES, INC. – 2026 PROXY STATEMENT SUMMARY CEO COMPENSATION & CHANGES • CEO Jason A. Okazaki's total compensation figures are not dis | 2026-04-22 |
| Annual report FY2025 ASSEMBLY BIOSCIENCES, INC. – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Public float (non-affiliate market value): $97.8 million as of Jun | 2026-03-19 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Assembly Biosciences Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.